xiaomei Li

Dr. xiaomei Li


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
DWDi Wu
Di Wu
JLJing Li
Jing Li
DXDong Xu
Dong Xu
JMJoan T Merrill
Joan T Merrill
RVRonald F van Vollenhoven
Ronald F van Vollenhoven
FZFengchun Zhang
Fengchun Zhang
Objectives This phase 2b, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of telitacicept, a novel fusion protein that neutralises signals of B lymphocyte stimulator and a proliferation-inducing ligand, in active systemic lupus erythematosus (SLE). Methods Adult patients with active SLE (n=249) were recruited from 29 hospitals in China and randomised 1:1:1:1 to receive subcutaneous telitacicept at 80 mg (n=62), 160 mg (n=63), 240 mg (n=62) or placebo (n=62) once weekly in addition to standard therapy. The primary endpoint was the proportion of patients achieving an SLE Responder Index 4 (SRI-4) response at week 48. Missing data were imputed using the last observation carried forward method. Results At week 48, the proportion of patients achieving an SRI-4 response was 75.8% in the 240 mg telitacicept group, 68.3% in the 160 mg group, 71.0% in the 80 mg group and 33.9% in the placebo group (all p<0.001). Significant treatment responses were observed in secondary endpoints, including a ≥4-point reduction on the Systemic Lupus Erythematosus Disease Activity Index, a lack of Physician’s Global Assessment score worsening and a glucocorticoid dose reduction in the 240 mg group. Telitacicept was well tolerated, and the incidence of adverse events and serious adverse events was similar between the telitacicept and placebo groups. Conclusions This phase 2b clinical trial met the primary endpoint. All telitacicept groups showed a significantly higher proportion of patients achieving an SRI-4 response than the placebo group at week 48, and all doses were well tolerated. These results support further investigations of telitacicept in clinical trials involving more diverse populations and larger sample sizes. Trial registration number ClinicalTrials.gov Registry (NCT02885610).

16 September 2023 in iScience
Verified
Journal Article
Open access
NXNan Xiang
Nan Xiang
HXHao Xu
Hao Xu
ZZZhou Zhou
Zhou Zhou
JWJunyu Wang
Junyu Wang
PCPengfei Cai
Pengfei Cai
XLxiaomei Li
xiaomei Li
Primary Sjögren’s syndrome (pSS) is a complex autoimmune disease characterized by lymphocytic infiltration and exocrine dysfunction, particularly affecting the salivary gland (SG). We employed single-cell RNA sequencing to investigate cellular heterogeneity in 11 patients with pSS and 5 non-SS controls. Notably, patients with pSS exhibited downregulated SOX9 in myoepithelial cells, potentially associated with impaired epithelial regeneration. An expanded ACKR1+ endothelial subpopulation in patients with pSS suggested a role in facilitating lymphocyte transendothelial migration. Our analysis of immune cells revealed expanded IGHD+ naive B cells in peripheral blood from patients with pSS. Pseudotime trajectory analysis outlined a bifurcated differentiation pathway for peripheral B cells, enriching three subtypes (VPREB3+ B, BANK1+ B, CD83+ B cells) within SGs in patients with pSS. Fibroblasts emerged as pivotal components in a stromal-immune interaction network, potentially driving extracellular matrix disruption, epithelial regeneration impairment, and inflammation. Our study illuminates immune and stromal cell heterogeneity in patients with pSS, offering insights into therapeutic strategies.

4 December 2018 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
CGCai‐Yue Gao
Cai‐Yue Gao
YYYuan Yao
Yuan Yao
LLLiang Li
Liang Li
SYShu‐Han Yang
Shu‐Han Yang
HCHui Chu
Hui Chu
ZLZhexiong Lian
Zhexiong Lian

30 April 2015 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
XLxiaomei Li
xiaomei Li
BXBei Xu
Bei Xu
YMYan Ma
Yan Ma
XLXiangpei Li
Xiangpei Li
QCQi Cheng
Qi Cheng
LWLi Wei
Li Wei

15 November 2007
Verified
Journal Article
Closed access
XLxiaomei Li
xiaomei Li
XLXiangpei Li
Xiangpei Li
LQLong Qian
Long Qian
GWGuosheng Wang
Guosheng Wang
HZHong Zhang
Hong Zhang
DHDavid C H Harris
David C H Harris

3 April 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
CLChun Li
Chun Li
JHJianlin Huang
Jianlin Huang
HWHuaxiang Wu
Huaxiang Wu
FLFen Li
Fen Li
YZYi Zhao
Yi Zhao
ZLZhanguo Li
Zhanguo Li
IMPORTANCE: Digital health applications have been shown to be effective in the management of chronic diseases with simple treatment targets. The potential clinical value of digital health applications in rheumatoid arthritis (RA) has not been well studied.OBJECTIVE: To investigate whether assessing patient-reported outcomes using digital health applications could result in disease control for patients with RA.DESIGN, SETTING, AND PARTICIPANTS: This is a multicenter, open-label randomized clinical trial in 22 tertiary hospitals across China. Eligible participants were adult patients with RA. Participants were enrolled from November 1, 2018, to May 28, 2019, with a 12-month follow-up. The statisticians and rheumatologists who assessed disease activity were blinded. Investigators and participants were not blind to group assignment. Analysis was conducted from October 2020 to May 2022.INTERVENTIONS: Participants were randomly assigned at a 1:1 ratio (block size of 4) to a smart system of disease management group (SSDM) or a conventional care control group. Upon the completion of the 6-month parallel comparison, patients in the conventional care control group were instructed to use the SSDM application for an extension of 6 months.MAIN OUTCOMES AND MEASURES: The primary outcome was the rate of patients with disease activity score in 28 joints using the C-reactive protein (DAS28-CRP) of 3.2 or less at month 6.RESULTS: Of 3374 participants screened, 2204 were randomized, and 2197 patients with RA (mean [SD] age, 50.5 [12.4] years; 1812 [82.5%] female) were enrolled. The study included 1099 participants in the SSDM group and 1098 participants in the control group. At month 6, the rate of patients with DAS28-CRP of 3.2 or less was 71.0% (780 of 1099 patients) in the SSDM group vs 64.5% (708 of 1098 patients) in the control group (difference between groups, 6.6%; 95% CI, 2.7% to 10.4%; P = .001). At month 12, the rate of patients with DAS28-CRP of 3.2 or less in the control group increased to a level (77.7%) that was comparable with that (78,2%) in the SSDM group (difference between groups, −0.2%; 95% CI, −3.9% to 3.4%; P = .90).CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of RA, the use of a digital health application with patient-reported outcomes was associated with an increase in disease control rate.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03715595